New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

Plus Therapeutics Inc. (NASDAQ:PSTV) said the U.S. Food and Drug Administration has granted Orphan Drug Designation to REYOBIQ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant ...

A significant unmet need exists for effective, low-toxicity early treatment in IDH-mutant gliomas, especially for younger patients and those with grade 2 tumors. Voranigo, an IDH1 and IDH2 inhibitor, ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Tafinlar and Mekinist combination therapy shows efficacy in glioma treatment for both pediatric and adult patients, with higher response rates in pediatric cases. Objective response rates were 53% for ...

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children.